Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.

Dupuis-Girod, Sophie

Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. [electronic resource] - JAMA Mar 2012 - 948-55 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

1538-3598

10.1001/jama.2012.250 doi


Angiogenesis Inhibitors--therapeutic use
Antibodies, Monoclonal, Humanized--therapeutic use
Arteriovenous Malformations--etiology
Bevacizumab
Cardiac Output--drug effects
Epistaxis--etiology
Female
Heart Failure
Humans
Liver--blood supply
Male
Middle Aged
Prospective Studies
Telangiectasia, Hereditary Hemorrhagic--complications
Treatment Outcome